FDA Approves First Medication Targeting the Root Cause of Narcolepsy Type 1

The U.S. Food and Drug Administration has approved Orzeyful (oveporexin) tablets for treating narcolepsy type 1 in adults, marking a significant breakthrough in sleep disorder treatment. This is the first medication specifically designed to address the biological root cause of narcolepsy type 1, which involves deficiency of orexin-producing neurons in the brain. Unlike previous treatments that only managed symptoms, Orzeyful directly targets the underlying neurological dysfunction, offering patients a new therapeutic approach. This FDA approval represents a major advancement for the approximately 135,000 Americans living with narcolepsy type 1, including residents of Puerto Rico who now have access to this innovative treatment option.